GBA Presents: House of Gummy-!

Discussion in 'Stocks' started by stonedinvestor, May 13, 2023.

  1. TRAGIC & AN OUTRAGE-

     
    #14481     Feb 28, 2024
  2. WHITE TRASH-

     
    #14482     Feb 28, 2024
    TrailerParkTed likes this.
  3. This is an interesting Co with 500+ employees- i have known them along time.

    Some take out chatter here.

    Company Profile
    [​IMG]
    Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
     
    #14483     Feb 28, 2024
  4. Way back in the day I owned this at $7. :confused: Oh.......... whatever.

    It reached $75 in 2019 :caution:

    It corrected to a $47--$25 channel
    Support at $23-$24

    NOW $34 not that far gone.

    ARWR Arrowhead Pharmaceuticals, Inc.

    $34.41 +3.24(+10.41%)

    Arrowhead Pharmaceuticals jumps amid takeover speculation
    NewsToday, 1:36 PM
     
    #14484     Feb 28, 2024
  5. 2022 high is around $50 so I would think at the very least that is what they would be asking for.. if the rumor is true.

    You would think if the rumor was true we would not see this:

    [​IMG]
     
    #14485     Feb 28, 2024
  6. Ditto here/ might be time to bail.

    [​IMG]
     
    #14486     Feb 28, 2024




  7. Update- kind of not stopping.

    IQV IQVIA Holdings Inc.
    15.17K followers
    $250.571.73(+0.70%)2:01 PM 02/28/24
    NYSE |
     
    #14487     Feb 28, 2024
  8. I forgot we were counting/// when I add up the last two weeks we are going to be over 17!
     
    #14488     Feb 28, 2024
  9. Well so far I have been very brave. Just Advil's.... but them Oxy's are a calling. I just don't want to turn into a junky or Trump voter.

     
    #14489     Feb 28, 2024
  10. Video Transcript

    AKIKO FUJITA: 34% of Americans who are vacationing this year plan to take a road trip. Now there are so many options for consumers out there. Outside of the usual gas powered car. Joining us now, as part of Yahoo Finance's travel guide 2024 industry insights, is our very own Pras Subramanian. Pras, something tells me you're going to stick to plug-ins. Not necessarily EVs for our road trip.

    PRAS SUBRAMANIAN: Yeah. I think so.



    • AKIKO FUJITA: Plug-in hybrids, I should say.

    PRAS SUBRAMANIAN: Well, yeah, I mean, you have hybrids that are plug-ins and not plug-ins, and have more electric power compared to others. But yeah, I mean, traditionally speaking, a road trip, look, with an EV, it's going to be a bit more difficult in terms of finding those charging stations across the highway. With Tesla, you might have a better opportunity there with the supercharger network.

    But yeah, looking at cars like in that hybrids and plug-ins. Consumer reports, they had a big report out yesterday talking about these cars and noting that hybrids and plug-in hybrids have been getting better over the years. Better technology, quieter more performance, better efficiency and things like that. And they broke down a comparison here. You can see this right now with an EV versus an equivalent plug-in hybrid.

    So in case, we're looking at, I believe the Kia Niro right. And when they did a study on how people actually travel and what their fuel costs or electrical costs would be. In this case, the plug-in hybrid, the PHEV Niro beats out the EV when it comes to actually running costs. So we see that there. The next example is the Hyundai Tucson which you'll see in the next screen. And that's a hybrid, traditional hybrid versus a PHEV.

    And guess what? In this case, the hybrid is beating the PHEV. Now I will say that this has to do with how the car is being used. So if you're doing a lot of highway driving, the PHEV will probably run out or probably not be going electric so much and that hybrid will actually give you more efficiency. But if you're doing a lot of city driving, the PHEV is going to be an all electric mode most of the time and you'll really save there in terms of energy prices.

    And finally the last example is the BMW 3 Series. The standard bearer there in the sedan market. The PHEV again beats out the traditional gas powered car here. Not surprising, you're going to get that extra efficiency that electric boost that'll improve or help your mileage there.

    AKIKO FUJITA: Pras, do we have any idea how available these cars are through rentals? And we've talked a lot about companies like Hertz really slashing their fleet around electric vehicles. Road trip typically requires-- typically you're out renting a car first before you head out on the road. What's the availability like?

    PRAS SUBRAMANIAN: I would argue that there's probably more EVs than PHEVs on the rental fleets currently. And now you said, you mentioned Hertz cutting their fleet. They still have several 1,000 EVs in their fleet. But I think prior to that, most traditional car rental companies were buying gas powered cars. Maybe a hybrid PHEVs were a bit more expensive and a bit more finicky with how you deal with it.

    You're not going to see or trust a car rental consumer to plug that in at night. Where are they going to do that? So I think you might see more traditional hybrids and maybe even more EVs now. But the plug-in hybrid was not part of the traditional car rental fleet. And I think you maybe you might see that change a bit as people become more accustomed to how those things work.

    Akiko, it's funny you mentioned one of the best selling plug-in hybrid is the Jeep Wrangler, PHEV and also the Grand Cherokee. It turns out a huge percentage of those users do not even know that you can plug-in that car to actually flip the battery. I'm telling you that's what dealers have told people like me and others. So there needs to be some education too.

    AKIKO FUJITA: Yeah. Education certainly key in that transition to electric. Pras Subramanian, thanks so much for that.
     
    #14490     Feb 28, 2024